Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models
Date:
Authors:
Herter S. Herting F. Mundigl O. Waldhauer I. Weinzierl T. Fauti T. Muth G. Ziegler-Landesberger D. Van Puijenbroek E. Lang S. Duong M. N. Reslan L. Gerdes C. A. Friess T. Baer U. Burtscher H. Weidner M. Dumontet C. Umana P. Niederfellner G. Bacac M. and Klein C
